Neuromuscular BlockadeNMB-old-ageNCT03551652
Comparison of Duration of Neuromuscular Block in Geriatric Patients Compared to Young Patients.
An observational study of Neuromuscular Blockade, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
Elderly people, especially geriatric patients, account for a growing share of patients receiving anesthesia. In patients over 75 years of age the annual rate of anesthesia represents 16.8 / 100 inhabitants for women and 19.6 / 100 for men. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neuromuscular Blockade
- What is being tested?
- Pharmacokinetics of rocuronium induced neuromuscular block
- How many people
- 28 participants
- Where
- 1 siteFrance
- Study dates
- 15 May 2020to 31 Mar 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients aged between 18-50 years or > 80 years, undergoing surgery with neuromuscular block induced by rocuronium
Who may be able to join
- Patients scheduled for surgery with neuromuscular blockade by rocuronium
- Body mass index between 18.5 and 35
- Age 18 - 50 years or age > 80 years
Who cannot join
- Known allergy to rocuronium
- rapid sequence induction
- clinical hepatocellular insufficiency
- renal insufficiency requiring dialysis
- ASA class > 2 in the group 18-50 years
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
CHRU de Nancy
Nancy, 54450
Thomas Fuchs-Buder, MD, +33383154166, t.fuchs-buder@chru-nancy.fr
About this study
Official title: Evaluation of Duration of Curarisation (Surgical Efficacy) and Pharmacokinetics of Neuromuscular Block After a Single Dose of Rocuronium in Geriatric Patients (Age ≥ 80 Years ) Compared to a Younger Population (Age < 50 Years).
Elderly people, especially geriatric patients, account for a growing share of patients receiving anesthesia.
In patients over 75 years of age the annual rate of anesthesia represents 16.8 / 100 inhabitants for women and 19.6 / 100 for men. It is a growing population, but also the most fragile population with a mortality amounting to 44.4 / 10000 anesthesia. After 85 years, one out of every two patients is ASA 3 or older.
Read more
The first cause of death related to anesthesia today remains respiratory complications, particularly infectious.
This is a major public health issue right now. The studies on the use of curare and particularly rocuronium are old and did not study a population of elderly people (with an average age of 70 years). Several studies show an increase in the duration of neuromuscular blockade in patients older than 70 years irrespective of any renal failure, with sometimes persistent curarizations more than 2h after a single dose. But no study to date has studied the duration of deep-intensity neuromuscular block (TOF).
Read the detailed description
Scientific justification Elderly patients, especially geriatric patients, represent an increasing percentage of patients receiving anesthesia. Thus, among the population over 75 years old, the annual rate of anesthesia represents 16.8 / 100 inhabitants. women and 19.6 / 100 in men. This is a growing population, but also the most fragile population with a mortality amounting to 44.4 / 10000 anesthesia. After 85 years, one out of every two anesthetized patients is ASA 3 or higher. The first cause of mortality linked to anesthesia today remains respiratory complications, particularly those of infectious origin. The care of this population presents a major public health challenge. Studies on the use of curare and especially rocuronium are relatively old and did not study a geriatric population, so in the group aged the average age was 70 years.
Several studies show an increase in the duration of neuromuscular blockade in patients over the age of 70, regardless of any renal failure, with extremes of persistent curarization more than 2 h after a single dose. However, no study to date has investigated the duration of deep-tissue neuromuscular blocking (train of four (TOF) <1) required for performing certain surgical procedures, including laparoscopic surgery.
Several studies show that elderly patients have increased sensitivity to residual curarization.
In this context, a study on the kinetics of the curare and in particular rocuronium is necessary in order to evaluate if the "standard" induction dose of 0.6 mg / kg is adapted to this population or if this dose requires an adjustment to reduce the respiratory risks associated with residual curarization.
General description of the research Objectives To compare the duration of curarization induced by rocuronium (0.6 mg / kg of real weight) between young patients (18-50 years old) and old men (> 80 years old).
Evaluation criteria
Primary judgment criterion:
Total curarization time (DCT, defined as the sum of the installation time + deep curarization time + recovery time The installation time (Dinstall) is defined as the time between the injection of rocuronium and the disappearance of the responses to the train of four (TOF = 0).
The deep block duration (Dprof) is defined as the time between the disappearance of the responses to the train of four (TOF = 0) and the reappearance of the first response to a train of four (TOF = 1).
The recovery time (Drécup) will be evaluated for both a T4 / T1 recovery ≥ 0.9 (Drécup0.9) and a T4 / T1 ratio ≥ 1.0 (Drécup1.0). recovery will also be assessed by the ratio of T4/Tref, i.e. the ratio of the 4th response to a TOF stimulation and the mean of the 4 responses to a TOF stimulation before administration of a neuromuscular blocking agent. This ratio is measured by the TofScan (IdMed, Marseille, France).
Research Methodology Patients will be anesthetized, as in clinical routine, with propofol in target controlled infusion anesthesia (TCI) according to the Schnider model at the effect site. Analgesia will be provided either by remifentanil or sufentanil.
Neuromuscular block will be monitored using TofScan (IdMed, Marseille, France), with accelerometry measurement at the adductor pollicis. The TOF-WatchSX will be calibrated in cal 2 mode, as defined by the manufacturer. (12) Neuromuscular blockade will be induced by a single dose of rocuronium 0.6 mg / kg of actual weight. The intensity of the neuromuscular block will be measured by a train of four every 15 s from the curare injection to TOF = 0 (Dinstall): then every minute until TOF = 1 (Dprof); then every minute until T4/T1 ≥ 0.9 (Drécup0.9) and T4/T1 ≥ 1.0 (Drécup1.0). Dinstall, Dprof, Drécup0.9 and Drécup1.0 will be recorded, as well as time to recovery of T4/Tref of 0.9 and 1.0.
Patient selection: inclusion and non-inclusion criteria, recruitment modality
Criteria for inclusion:
- Patient aged 18 to 50 or ≥ 80 years
- Body mass index (BMI) between 18.5 and 35
- Intervention requiring general anesthesia with intubation
Criteria of non-inclusion:
- Rocuronium allergy
- Need for rapid sequence induction
- Clinically apparent hepatocellular insufficiency
- Renal insufficiency requiring dialysis
- ASA> 2 in the group of 18 to 50 years
Materials and techniques used Monitoring of the TofScan (IdMed, Marseille, France) monitor at the level of the adductor pollicis. The electrodes are placed at the ulnar edge of the arm 2 cm apart.12 Registration of the Tref value before administration of rocuronium. Measurement of the neuromuscular block intensity every 15s from the neuromuscular blocking facility to TOF = 0, then measured every minute of the neuromuscular block up to TOF = 1(Dprof) and finally measured every minute until decurarisation spontaneous T4 / T1 ≥ 0.9 (Drécup0.9) and T4 / T1 ≥ 1.0 (Trécup1.0). The time to recovery of T4/Tref to 0.9 and 1.0 ill also be recorded.
Normothermia is maintained (temperature> 36 ° C) by the use of a forced air system (Bair Hugger) with temperature monitoring by oesophageal probe.
Statistics
Number of patients:
To estimate the number of patients to be included in each group, we postulate that the DCT of patients 80 and over is, on average, at least 30% greater than the CSD of patients under 50 years of age.
The mean DCT of the under-50 group is around 60 minutes and a standard deviation of 11 minutes. By setting the alpha risk at 5% and the expected power 80%, it will be necessary to include 14 patients per group, or 28 in total.
Statistical analysis :
Descriptive analysis: calculation of%, means, standard deviations, quartiles and extreme values Principal analysis: the mean DCT will be compared by a matched series average comparison test, then by a linear regression model with adjustment for potential confounders, excluding matching factors.
Secondary analyzes: The secondary endpoints will be compared by a MacNémar test and a Student's t-test on matched series and possibly by conditional logistic and linear regression models to allow an adjustment for potential confounding factors.
Threshold of significance: 5% Software: SAS v9.4
- Conditions
- Neuromuscular Blockade
- Being tested
- Pharmacokinetics of rocuronium induced neuromuscular block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pharmacokinetics of rocuronium induced neuromuscular blockDrug
Measurement of rocuronium induced neuromuscular block comparing patients aged > 80 years with patients aged 18 to 50 years
| Study group | Role | What they receive |
|---|---|---|
| Young patients | Patients aged 18 - 50 years Receives: Drug: Pharmacokinetics of rocuronium induced neuromuscular block | |
| Geriatric patients | Patients aged ≥ 80 years Receives: Drug: Pharmacokinetics of rocuronium induced neuromuscular block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total time of neuromuscular block
Time from rocuronium injection to total recovery of neuromuscular block
Measured: 4 hours, during surgery
Secondary outcomes (5)
Deep neuromuscular block
Time between TOF=0 and TOF=1
Measured: 4 hours, during surgery
Recovery time 0.9
Time between TOF=0 and T4/T1≥0.9
Measured: 4 hours, during surgery
Recovery time 1.0
Time between TOF=0 and T4/T1≥1.0
Measured: 4 hours, during surgery
Recovery time 0.9 Tref
Time between TOF=0 and T4/Tref≥0.9
Measured: 4 hours, during surgery
Recovery time 1.0 Tref
Time between TOF=0 and T4/Tref≥1.0
Measured: 4 hours, during surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2018
- Study start15 May 2020
- Primary completion31 Mar 2021 (estimated)
- Study completion31 Mar 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for Neuromuscular BlockadeStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 28 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Thomas Fuchs-Buder, MD, PhD, Principal investigator, CHRU de Nancy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03551652
- Sponsor's protocol ID
- NMB-old-age
- Acronym
- NMB-old-age
- Status last verified
- Nov 2020
- First submitted
- 29 May 2018
- Last updated
- 1 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Klopfenstein CE, Herrmann FR, Michel JP, Clergue F, Forster A. The influence of an aging surgical population on the anesthesia workload: a ten-year survey. Anesth Analg. 1998 Jun;86(6):1165-70. doi: 10.1097/00000539-199806000-00005.
PubMed 9620497Auroy Y, Laxenaire MC, Clergue F, Pequignot F, Jougla E, Lienhart A. [Anesthetics according to characteristics of patients, establishments and indications]. Ann Fr Anesth Reanim. 1998;17(11):1311-6. doi: 10.1016/s0750-7658(99)80043-4. No abstract available. French.
PubMed 9972358Forrest JB, Rehder K, Cahalan MK, Goldsmith CH. Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes. Anesthesiology. 1992 Jan;76(1):3-15. doi: 10.1097/00000542-199201000-00002.
PubMed 1729933Pignaton W, Braz JRC, Kusano PS, Modolo MP, de Carvalho LR, Braz MG, Braz LG. Perioperative and Anesthesia-Related Mortality: An 8-Year Observational Survey From a Tertiary Teaching Hospital. Medicine (Baltimore). 2016 Jan;95(2):e2208. doi: 10.1097/MD.0000000000002208.
PubMed 26765400Tiret L, Desmonts JM, Hatton F, Vourc'h G. Complications associated with anaesthesia--a prospective survey in France. Can Anaesth Soc J. 1986 May;33(3 Pt 1):336-44. doi: 10.1007/BF03010747.
PubMed 3719435Yamamoto H, Uchida T, Yamamoto Y, Ito Y, Makita K. Retrospective analysis of spontaneous recovery from neuromuscular blockade produced by empirical use of rocuronium. J Anesth. 2011 Dec;25(6):845-9. doi: 10.1007/s00540-011-1229-x. Epub 2011 Sep 21.
PubMed 21935686Comparison of Neuromuscular Blockade with Rocuronium in Young and Elderly Patients with or without Renal Failure. 1SK Gvalani, 2L Pradeep Research & Innovation in Anesthesia, July-December 2016;1(2):45-51
Bevan DR, Fiset P, Balendran P, Law-Min JC, Ratcliffe A, Donati F. Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anaesth. 1993 Feb;40(2):127-32. doi: 10.1007/BF03011309.
PubMed 8443851Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear TD, Vender JS, Parikh KN, Patel SS, Patel A. Residual Neuromuscular Block in the Elderly: Incidence and Clinical Implications. Anesthesiology. 2015 Dec;123(6):1322-36. doi: 10.1097/ALN.0000000000000865.
PubMed 26448469Arain SR, Kern S, Ficke DJ, Ebert TJ. Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta Anaesthesiol Scand. 2005 Mar;49(3):312-5. doi: 10.1111/j.1399-6576.2005.00634.x.
PubMed 15752394Kocabas S, Yedicocuklu D, Askar FZ. The neuromuscular effects of 0.6 mg kg(-1) rocuronium in elderly and young adults with or without renal failure. Eur J Anaesthesiol. 2008 Nov;25(11):940-6. doi: 10.1017/S0265021508004717. Epub 2008 Jun 9.
PubMed 18538050Neuromuskuläres Monitoring in Klinik und Forschung. T. Fuchs-Buder, Springer Medezin Verlag, 2008, ISBN 978-3-540-78569-9
Schmartz D, Sghaier R, Bernard P, Fils JF, Fuchs-Buder T. Neuromuscular block in patients 80 years and older: a prospective, controlled study. BMC Anesthesiol. 2021 Sep 13;21(1):225. doi: 10.1186/s12871-021-01443-1.
PubMed 34517841
Study at a glance
From the registry record, last updated by the sponsor on 1 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Duration of Curarisation (Surgical Efficacy) and Pharmacokinetics of Neuromuscular Block After a Single Dose of Rocuronium in Geriatric Patients (Age ≥ 80 Years ) Compared to a Younger Population (Age < 50 Years).
- ClinicalTrials.gov ID
- NCT03551652
- Acronym / sponsor ID
- NMB-old-age / NMB-old-age
- Conditions
- Neuromuscular Blockade
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 28 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 15 May 2020 (actual)
- Primary completion
- 31 Mar 2021 (estimated)
- Study completion
- 31 Mar 2021 (estimated)
- First posted
- 11 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Elderly people, especially geriatric patients, account for a growing share of patients receiving anesthesia.
In patients over 75 years of age the annual rate of anesthesia represents 16.8 / 100 inhabitants for women and 19.6 / 100 for men. It is a growing population, but also the most fragile population with a mortality amounting to 44.4 / 10000 anesthesia. After 85 years, one out of every two patients is ASA 3 or older.
The first cause of death related to anesthesia today remains respiratory complications, particularly infectious.
This is a major public health issue right now. The studies on the use of curare and particularly rocuronium are old and did not study a population of elderly people (with an average age of 70 years). Several studies show an increase in the duration of neuromuscular blockade in patients older than 70 years irrespective of any renal failure, with sometimes persistent curarizations more than 2h after a single dose. But no study to date has studied the duration of deep-intensity neuromuscular block (TOF).
Detailed description
Scientific justification Elderly patients, especially geriatric patients, represent an increasing percentage of patients receiving anesthesia. Thus, among the population over 75 years old, the annual rate of anesthesia represents 16.8 / 100 inhabitants. women and 19.6 / 100 in men. This is a growing population, but also the most fragile population with a mortality amounting to 44.4 / 10000 anesthesia. After 85 years, one out of every two anesthetized patients is ASA 3 or higher. The first cause of mortality linked to anesthesia today remains respiratory complications, particularly those of infectious origin. The care of this population presents a major public health challenge. Studies on the use of curare and especially rocuronium are relatively old and did not study a geriatric population, so in the group aged the average age was 70 years.
Several studies show an increase in the duration of neuromuscular blockade in patients over the age of 70, regardless of any renal failure, with extremes of persistent curarization more than 2 h after a single dose. However, no study to date has investigated the duration of deep-tissue neuromuscular blocking (train of four (TOF) <1) required for performing certain surgical procedures, including laparoscopic surgery.
Several studies show that elderly patients have increased sensitivity to residual curarization.
In this context, a study on the kinetics of the curare and in particular rocuronium is necessary in order to evaluate if the "standard" induction dose of 0.6 mg / kg is adapted to this population or if this dose requires an adjustment to reduce the respiratory risks associated with residual curarization.
General description of the research Objectives To compare the duration of curarization induced by rocuronium (0.6 mg / kg of real weight) between young patients (18-50 years old) and old men (> 80 years old).
Evaluation criteria
Primary judgment criterion:
Total curarization time (DCT, defined as the sum of the installation time + deep curarization time + recovery time The installation time (Dinstall) is defined as the time between the injection of rocuronium and the disappearance of the responses to the train of four (TOF = 0).
The deep block duration (Dprof) is defined as the time between the disappearance of the responses to the train of four (TOF = 0) and the reappearance of the first response to a train of four (TOF = 1).
The recovery time (Drécup) will be evaluated for both a T4 / T1 recovery ≥ 0.9 (Drécup0.9) and a T4 / T1 ratio ≥ 1.0 (Drécup1.0). recovery will also be assessed by the ratio of T4/Tref, i.e. the ratio of the 4th response to a TOF stimulation and the mean of the 4 responses to a TOF stimulation before administration of a neuromuscular blocking agent. This ratio is measured by the TofScan (IdMed, Marseille, France).
Research Methodology Patients will be anesthetized, as in clinical routine, with propofol in target controlled infusion anesthesia (TCI) according to the Schnider model at the effect site. Analgesia will be provided either by remifentanil or sufentanil.
Neuromuscular block will be monitored using TofScan (IdMed, Marseille, France), with accelerometry measurement at the adductor pollicis. The TOF-WatchSX will be calibrated in cal 2 mode, as defined by the manufacturer. (12) Neuromuscular blockade will be induced by a single dose of rocuronium 0.6 mg / kg of actual weight. The intensity of the neuromuscular block will be measured by a train of four every 15 s from the curare injection to TOF = 0 (Dinstall): then every minute until TOF = 1 (Dprof); then every minute until T4/T1 ≥ 0.9 (Drécup0.9) and T4/T1 ≥ 1.0 (Drécup1.0). Dinstall, Dprof, Drécup0.9 and Drécup1.0 will be recorded, as well as time to recovery of T4/Tref of 0.9 and 1.0.
Patient selection: inclusion and non-inclusion criteria, recruitment modality
Criteria for inclusion:
- Patient aged 18 to 50 or ≥ 80 years
- Body mass index (BMI) between 18.5 and 35
- Intervention requiring general anesthesia with intubation
Criteria of non-inclusion:
- Rocuronium allergy
- Need for rapid sequence induction
- Clinically apparent hepatocellular insufficiency
- Renal insufficiency requiring dialysis
- ASA> 2 in the group of 18 to 50 years
Materials and techniques used Monitoring of the TofScan (IdMed, Marseille, France) monitor at the level of the adductor pollicis. The electrodes are placed at the ulnar edge of the arm 2 cm apart.12 Registration of the Tref value before administration of rocuronium. Measurement of the neuromuscular block intensity every 15s from the neuromuscular blocking facility to TOF = 0, then measured every minute of the neuromuscular block up to TOF = 1(Dprof) and finally measured every minute until decurarisation spontaneous T4 / T1 ≥ 0.9 (Drécup0.9) and T4 / T1 ≥ 1.0 (Trécup1.0). The time to recovery of T4/Tref to 0.9 and 1.0 ill also be recorded.
Normothermia is maintained (temperature> 36 ° C) by the use of a forced air system (Bair Hugger) with temperature monitoring by oesophageal probe.
Statistics
Number of patients:
To estimate the number of patients to be included in each group, we postulate that the DCT of patients 80 and over is, on average, at least 30% greater than the CSD of patients under 50 years of age.
The mean DCT of the under-50 group is around 60 minutes and a standard deviation of 11 minutes. By setting the alpha risk at 5% and the expected power 80%, it will be necessary to include 14 patients per group, or 28 in total.
Statistical analysis :
Descriptive analysis: calculation of%, means, standard deviations, quartiles and extreme values Principal analysis: the mean DCT will be compared by a matched series average comparison test, then by a linear regression model with adjustment for potential confounders, excluding matching factors.
Secondary analyzes: The secondary endpoints will be compared by a MacNémar test and a Student's t-test on matched series and possibly by conditional logistic and linear regression models to allow an adjustment for potential confounding factors.
Threshold of significance: 5% Software: SAS v9.4
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Young patients | – | Drug: Pharmacokinetics of rocuronium induced neuromuscular blockPatients aged 18 - 50 years |
| Geriatric patients | – | Drug: Pharmacokinetics of rocuronium induced neuromuscular blockPatients aged ≥ 80 years |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients aged between 18-50 years or > 80 years, undergoing surgery with neuromuscular block induced by rocuronium
Key inclusion criteria (3 listed)
- Patients scheduled for surgery with neuromuscular blockade by rocuronium
- Body mass index between 18.5 and 35
- Age 18 - 50 years or age > 80 years
Key exclusion criteria (5 listed)
- Known allergy to rocuronium
- rapid sequence induction
- clinical hepatocellular insufficiency
- renal insufficiency requiring dialysis
- ASA class > 2 in the group 18-50 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pharmacokinetics of rocuronium induced neuromuscular blockMeasurement of rocuronium induced neuromuscular block comparing patients aged > 80 years with patients aged 18 to 50 years | Drug | Geriatric patients, Young patients |
Primary outcome
Total time of neuromuscular block
Time frame: 4 hours, during surgery
Time from rocuronium injection to total recovery of neuromuscular block
5 secondary outcomes
Deep neuromuscular block
Time frame: 4 hours, during surgery
Recovery time 0.9
Time frame: 4 hours, during surgery
Recovery time 1.0
Time frame: 4 hours, during surgery
Recovery time 0.9 Tref
Time frame: 4 hours, during surgery
Recovery time 1.0 Tref
Time frame: 4 hours, during surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Feb 2021.
- Background: PubMed 9620497Klopfenstein CE, Herrmann FR, Michel JP, Clergue F, Forster A. The influence of an aging surgical population on the anesthesia workload: a ten-year survey. Anesth Analg. 1998 Jun;86(6):1165-70. doi: 10.1097/00000539-199806000-00005.
- Background: PubMed 9972358Auroy Y, Laxenaire MC, Clergue F, Pequignot F, Jougla E, Lienhart A. [Anesthetics according to characteristics of patients, establishments and indications]. Ann Fr Anesth Reanim. 1998;17(11):1311-6. doi: 10.1016/s0750-7658(99)80043-4. No abstract available. French.
- Background: PubMed 1729933Forrest JB, Rehder K, Cahalan MK, Goldsmith CH. Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes. Anesthesiology. 1992 Jan;76(1):3-15. doi: 10.1097/00000542-199201000-00002.
- Background: PubMed 26765400Pignaton W, Braz JRC, Kusano PS, Modolo MP, de Carvalho LR, Braz MG, Braz LG. Perioperative and Anesthesia-Related Mortality: An 8-Year Observational Survey From a Tertiary Teaching Hospital. Medicine (Baltimore). 2016 Jan;95(2):e2208. doi: 10.1097/MD.0000000000002208.
- Background: PubMed 3719435Tiret L, Desmonts JM, Hatton F, Vourc'h G. Complications associated with anaesthesia--a prospective survey in France. Can Anaesth Soc J. 1986 May;33(3 Pt 1):336-44. doi: 10.1007/BF03010747.
- Background: PubMed 21935686Yamamoto H, Uchida T, Yamamoto Y, Ito Y, Makita K. Retrospective analysis of spontaneous recovery from neuromuscular blockade produced by empirical use of rocuronium. J Anesth. 2011 Dec;25(6):845-9. doi: 10.1007/s00540-011-1229-x. Epub 2011 Sep 21.
- BackgroundComparison of Neuromuscular Blockade with Rocuronium in Young and Elderly Patients with or without Renal Failure. 1SK Gvalani, 2L Pradeep Research & Innovation in Anesthesia, July-December 2016;1(2):45-51
- Background: PubMed 8443851Bevan DR, Fiset P, Balendran P, Law-Min JC, Ratcliffe A, Donati F. Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anaesth. 1993 Feb;40(2):127-32. doi: 10.1007/BF03011309.
- Background: PubMed 26448469Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear TD, Vender JS, Parikh KN, Patel SS, Patel A. Residual Neuromuscular Block in the Elderly: Incidence and Clinical Implications. Anesthesiology. 2015 Dec;123(6):1322-36. doi: 10.1097/ALN.0000000000000865.
- Background: PubMed 15752394Arain SR, Kern S, Ficke DJ, Ebert TJ. Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta Anaesthesiol Scand. 2005 Mar;49(3):312-5. doi: 10.1111/j.1399-6576.2005.00634.x.
- Background: PubMed 18538050Kocabas S, Yedicocuklu D, Askar FZ. The neuromuscular effects of 0.6 mg kg(-1) rocuronium in elderly and young adults with or without renal failure. Eur J Anaesthesiol. 2008 Nov;25(11):940-6. doi: 10.1017/S0265021508004717. Epub 2008 Jun 9.
- BackgroundNeuromuskuläres Monitoring in Klinik und Forschung. T. Fuchs-Buder, Springer Medezin Verlag, 2008, ISBN 978-3-540-78569-9
- Individual participant dataSharing planned: No
Related trials for Neuromuscular Blockade
Active, not recruiting
Efficacy of Laparoscopic-Assisted TAP Block in Laparoscopic Appendectomy
Appendectomy, Laparoscopic, Blockades Neuromuscular
Not yet recruitingObservational study
Diaphragm Ultrasound and Neuromuscular Monitoring for Predicting Early Respiratory Events After Extubation
Residual Neuromuscular Blockade, Diaphragm Dysfunction
Recruiting
Inspiratory Muscle Training and Diaphragmatic Breathing in GAD
Generalized Anxiety Disorder (GAD)
Not yet recruiting
Comparative Effects Of Exercises Targeting Upper Trapezius In Patients With Non Specific Neck Pain
Non Specific Neck Pain
RecruitingObservational study
The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio
Muscle Relaxants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Fuchs-Buder, MD, PhD principal investigator
CHRU de Nancy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuromuscular Blockade, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Thomas Fuchs-Buder, MD, PhD (+33383154166, t.fuchs-buder@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total time of neuromuscular block (time frame: 4 hours, during surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03551652, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2021.